1. Home
  2. RDHL vs AIMD Comparison

RDHL vs AIMD Comparison

Compare RDHL & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

N/A

Current Price

$0.63

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

Logo Ainos Inc.

AIMD

Ainos Inc.

N/A

Current Price

$1.45

Market Cap

11.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RDHL
AIMD
Founded
2009
1984
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
11.5M
IPO Year
2012
2008

Fundamental Metrics

Financial Performance
Metric
RDHL
AIMD
Price
$0.63
$1.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
31.7K
32.5K
Earning Date
04-27-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$124,157.00
Revenue This Year
$381.91
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
498.95
52 Week Low
$0.57
$1.26
52 Week High
$2.79
$4.44

Technical Indicators

Market Signals
Indicator
RDHL
AIMD
Relative Strength Index (RSI) 45.32 43.57
Support Level $0.58 $1.35
Resistance Level $0.73 $1.65
Average True Range (ATR) 0.05 0.13
MACD 0.01 0.02
Stochastic Oscillator 44.36 41.07

Price Performance

Historical Comparison
RDHL
AIMD

About RDHL Redhill Biopharma Ltd.

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.

Share on Social Networks: